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A systematic review and
pooled analysis was per-
formed to compare stereo-
tactic body radiation therapy
(SBRT) and radiofrequency
ablation (RFA) in inoperable
stage I NSCLC. A compre-
hensive literature search for
published trials from the last
15 years was undertaken.
The local tumor control rate
(LCR) at 1, 2, 3, and 5 years
for RFA was significantly
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http://dx.doi.org/10.1016/j.ijrobp.2016.04.016Purpose: To performed a systematic review and pooled analysis to compare clinical
outcomes of stereotactic body radiation therapy (SBRT) and radiofrequency ablation
(RFA) for the treatment of medically inoperable stage I non-small cell lung cancer.
Methods and Materials: A comprehensive literature search for published trials from
2001 to 2012 was undertaken. Pooled analyses were performed to obtain overall sur-
vival (OS) and local tumor control rates (LCRs) and adverse events. Regression anal-
ysis was conducted considering each study’s proportions of stage IA and age.
Results: Thirty-one studies on SBRT (2767 patients) and 13 studies on RFA (328 pa-
tients) were eligible. The LCR (95% confidence interval) at 1, 2, 3, and 5 years for
RFA was 77% (70%-85%), 48% (37%-58%), 55% (47%-62%), and 42%
(30%-54%) respectively, which was significantly lower than that for SBRT: 97%
(96%-98%), 92% (91%-94%), 88% (86%-90%), and 86% (85%-88%) (P<.001).
These differences remained significant after correcting for stage IA and age
(P<.001 at 1 year, 2 years, and 3 years; PZ.04 at 5 years). The effect of RFA was
not different from that of SBRT on OS (P>.05). The most frequent complication ofe can be taken at http://
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remained significant after
correcting for stage IA and
age. However, caution is
warranted owing to the
limited number of RFA
studies.RFA was pneumothorax, occurring in 31% of patients, whereas that for SBRT (grade
3) was radiation pneumonitis, occurring in 2% of patients.
Conclusions: Compared with RFA, SBRT seems to have a higher LCR but similar OS.
More studies with larger sample sizes are warranted to validate such findings.  2016
The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Nearly 25% of patients with early-stage or stage I non-
small cell lung cancer (NSCLC) are considered medically
inoperable (1, 2), with 5-year survival rates of only
approximately 15% before the era of stereotactic body ra-
diation therapy (SBRT), which are significantly poorer than
for those who receive surgery (2, 3). Local failure was the
primary cause of failure (4, 5). Stereotactic body radiation
therapy, which is also referred to as stereotactic ablative
radiation therapy, has emerged as an important treatment
option for inoperable stage I NSCLC over the last 10 years.
This radiation technology allows accurate delivery of a very
high dose to the tumor, while sparing normal adjacent tis-
sue. In prospective and large retrospective multicenter
studies, when an adequate dose (biologically equivalent
dose [BED] 100 Gy) is used, high local control rates
(LCRs) of more than 90% have been reported, as well as
promising overall survival (OS) advantages and good
tolerance compared with conventional radiation therapy (6,
7, 8). The recently published results from the Radiation
Therapy Oncology Group 0236 trial demonstrated a 3-year
actuarial LCR of 98%, while altogether avoiding severe
toxicity in more than 75% of treated patients (8). With this
and other evidence, SBRT is the current standard of care for
medically inoperable stage I NSCLC.
Radiofrequency ablation (RFA) is another promising
nonsurgical therapeutic alternative for small, peripheral tumors.
It can be performed percutaneously, under conscious sedation
and image guidance, and as an outpatient procedure or with a
short hospital stay. The use ofRFA to treat lungmalignancies in
human was first reported in 2000 (9). The largest prospective,
multicenter trial of RFA for lung tumors was the RAPTURE
studypublished in2008,which enrolled106 inoperablepatients
with 183 lung tumors, including 33 primary NSCLC patients
(10). A 75% 2-year OS has been shown in patients with stage I
NSCLC (nZ13), and a confirmed complete response lasting at
least 1 year was 88%. Radiofrequency ablation treatment was
well tolerated. Major complications were symptomatic
pneumothorax needing drainage (nZ27) and pleural effusion
needing drainage (nZ4). Minor complications were
pneumothorax (nZ28) or pleural effusion (nZ11) not needing
treatment and self-limiting intrapulmonaryhemorrhage (nZ3).
However, the majority of RFA studies in early-stage NSCLC
are small case series, and the reported LCRs ranged greatly
from 58% to 95% (11, 12, 13, 14).At present no direct comparison of clinical outcomes
between RFA and SBRT has been published. Furthermore,
it is often challenging for a tumor board to decide between
RFA and SBRT, because many patients are candidates for
both treatments, and it is unknown which treatment would
provide superior outcome. In addition, outcome data from
randomized studies are lacking, and no such prospective
trial is ongoing. Therefore, we performed this systemic
review and pooled analysis to provide a comparison be-
tween RFA and SBRT, for treatment of medically inoper-
able stage I NSCLC, with a focus on LCR, OS, and
treatment-related toxicities.
Methods and Materials
A comprehensive literature search was performed using
MEDLINE, Embase, and the Cochrane Library from 2001
to 2012. Specific search terms used included the following:
radiofrequency ablation, thermal ablation, stereotactic ra-
diation therapy, stereotactic radiation therapy, stereotactic
ablative radiation therapy, non-small cell lung carcinoma,
and NSCLC. Reference lists of obtained articles were
searched as well.
Inclusion and exclusion criteria
The eligibility criteria included were as follows: (1) stage I
NSCLC diagnosis; (2) medically inoperability; and (3)
reporting on the outcome of patients after RFA or SBRT.
Outcome data included LCRs at 1, 2, 3, and 5 years, and OS
rates at 1, 2, 3, and 5 years. Local control was assessed by
follow-up radiologic image and defined as no tumor
recurrence/progression in the primary site. Procedure-
related morbidity and mortality were also analyzed.
Studies about RFA followed by immediate resection or
radiation therapy, or SBRT with BED <100 Gy, fraction
dose <8 Gy, or using more than 5 fractions, or with fewer
than 5 patients in the RFA group and 30 patients in the
SBRT group were excluded. We limited the SBRT to 5
fractions or less to make the patient population more
comparable to that of RFA (ie, peripheral location). Case
reports, review articles, unpublished data, and publications
in languages other than English were also excluded from
further analysis. Studies and/or subgroups were included if
reporting sufficient data on LCR, OS, and treatment-related
morbidity. In case of potential duplication or overlapping
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included, according to published information.
Data extraction
One investigator (N.B.) identified the articles for this topic.
Two investigators (N.B., X.Z.) extracted the data on study
characteristics, study population, technical details, and
outcome measurements using a standardized Excel file and
reached consensus on all items. No attempt was made to get
missing data from the authors. The BED10 was calculated
according to the following linear-quadratic equation:
BED10Znd  [1 þ d/(a/b)], where a/bZ10 and n and
d represent the number of fractions and the dose per frac-
tion, respectively. The 1-, 2-, 3-, and 5-year LCR and OS
were extracted from each study if available, as well as the
occurrence of adverse events. In studies in which survival
rates were not explicitly stated but Kaplan-Meier survival
curves were provided, survival data were extracted from
survival curves.
In stage I NSCLC the occurrence of severe adverse
events (Common Terminology Criteria for Adverse Events
grade 3-5) was infrequent for all treatment modalities. The
majority of SBRT studies reported zero adverse events;
therefore, we added up the adverse events occurring for
each treatment modality instead of pooling the estimates
using a regression. Proportions and 95% confidence in-
tervals (CIs) were calculated using a binomial distribution.
Data analysis
The primary endpoint of this study was LCR at 3 years.
Secondary endpoints were OS and treatment-related
thoracic toxicity.
A pooled analysis was used to determine weighted
summary statistics for each of the treatments. The results
were presented as pooled proportions of patients surviving
(or local progression-free surviving) 1, 2, 3, and 5 years
from diagnosis, with 95% CIs. Because standard errors for
the surviving proportions of patients were not consistently
reported, we inferred them from the reported median follow-
up times using the parametric bootstrap (15). Application of
the parametric bootstrap to survival data requires models for
both the survival and censoring processes. To obtain a model
for the population survival process, for each study, a model
was fit to the reported survival times (at 1, 2, 3, and 5 years
as reported). For studies with only 1 reported follow-up
time, a 1-parameter exponential model was used. For
studies with 2 or more reported follow-up times, a 2-
parameter Weibull model was used. The right tail of the
population survival curve was fit to the reported surviving
patient fractions using least squares. The censoring process
was modeled as an exponential distribution, with median
equal to the reported median follow-up time. Simulation was
then used to estimate the standard errors for estimating the
surviving patient fractions, based on data sets of the reportedsample size, from the estimated survival and censoring
processes. Because differences between the characteristics
of the study populations may influence the effectiveness of
different treatment modalities, regression analysis was per-
formed considering each study’s proportions of stage IA and
patients’ age. All the analyses were done using R language
(www.r-project.org).
Results
Literature search
The literature search performed in July 2012 yielded 1270
articles (Fig. 1). Among them, 478 articles were found to be
pertinent. Three hundred six studies were excluded because
they failed to meet the eligibility criteria on the basis of the
screening of the titles and abstracts. Of the remaining 172
references, the full texts were retrieved and the data
analyzed. One additional reference on RFA was retrieved
through manual searches of the reference lists. Ultimately,
44 articles were found to report data of interest and fulfilled
the inclusion criteria of the present study: 13 studies
including 328 patients on RFA (10-14, 16-23) and 31 studies
including 2767 patients on SBRT (6-8, 24-51). There were
no randomized, controlled trials or nonrandomized studies
directly comparing the differences between RFA and SBRT.
All eligible studies were single-arm observational studies or
subgroups of comparative studies. Tables 1 and 2 summarize
the main characteristics of these studies.
Local control for medically inoperable stage I
NSCLC
Forty studies reported LCRs (Fig. 2 and Table 3). In the
RFA group, 5 studies (142 patients) reported 1-year LCR, 4
studies (113 patients) reported 2-year LCR, 6 studies (248
patients) reported 3-year LCR, and 4 studies (106 patients)
reported 5-year LCR. In the SBRT group, 20 studies (2107
patients) reported 1-year LCR, 22 studies (2137 patients)
reported 2-year LCR, 21 studies (2151 patients) reported 3-
year LCR, and 6 studies (1192 patients) reported 5-year
LCR. The results of the fixed-effect pooled analysis on
LCR are presented in Table 3. The 1-, 2-, 3-, and 5-year
LCR estimates and their 95% CIs were 77% (70%-85%),
48% (37%-58%), 55% (47%-62%), and 42% (30%-54%)
for RFA and 97% (96%-98%), 92% (91%-94%), 88%
(86%-90%), and 86% (85%-88%) for SBRT, respectively.
The uncorrected pooled 1-, 2-, 3-, 5-year LCRs for RFA
were all significantly lower than those for SBRT (all
P<.001).
Overall survival for medically inoperable stage I
NSCLC
All studies reported OS (Fig. 3 and Table E1; available online
at www.redjournal.org). In the RFA group, 12 studies (313
1270 potential papers identified
478 screened on the basis of title 
and abstract
745 studies excluded
172 full-text articles assessed for  
eligibility and exclusion criteria
44 studies included in the meta  
analysis
306 studies excluded (limited to “RFA or 
SBRT," and “medically inoperable stage I 
NSCLC” ) 
129 studies excluded (overlapping, without 
relevant data, less than 5 patients for RFA, 
or less than 30 patients for SBRT )
Case reports/comments/editorials/ 
reviews or meta-analysis n=53 
Not in English n=82 
Duplicated studies n=222 
Non-pertinent studies n=435 
1 study included by hand searched
references
Fig. 1. Flowchart of literature search and review. Abbreviations: NSCLC Z non-small cell lung cancer;
RFA Z radiofrequency ablation; SBRT Z stereotactic body radiation therapy.
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ported 2-year OS, 9 studies (240 patients) reported 3-year OS,
and 8 studies (216 patients) reported 5-year OS. In the SBRT
group, 27 studies (2467 patients) reported 1-year OS, 26
studies (2377 patients) reported 2-year OS, 21 studies (2003
patients) reported 3-year OS, and 10 studies (1503 patients)
reported 5-year OS. The results of the fixed-effect pooled
analysis on OS are presented in Table E1 (available online at
www.redjournal.org). The 1-, 2-, 3-, and 5-year OS estimates
and their 95% CIs were 85% (80%-89%), 67% (61%-74%),
53% (45%-61%), and 32% (22%-43%) for RFA and 85%
(84%-87%), 68% (66%-70%), 56% (53%-59%), and 40%Table 1 Characteristics for radiofrequency ablation studies (2001-2
First author (reference) Year
Study
design Sample size Male (%)
Belfiore (17) 2004 R 33 79
Pennathur (14) 2007 R 19 42
Simon (21) 2007 R 75 57
Lencioni (10) 2008 P 33 76
Okuma (13) 2010 R 7 78
Zemlyak (23) 2010 R 12 56
Ambrogi (16) 2011 P 59 79
Hess (11) 2011 R 15 60
Hiraki (12) 2011 R 50 58
Lee (20) 2011 R 16 75
Sofocleous (22) 2011 R 12 67
Kim (18) 2012 R 8 88
Lanuti (19) 2012 R 45 40
Abbreviations: F/UZ follow-up period; IA/IZ percentage of patients with
Path. Z percentage of disease with pathologic confirmation; R Z retrospectiv(36%-45%) for SBRT. Neither treatment had significantly
different uncorrected 1-, 2-, 3-, and 5-year OS (all P>.05).Comparison between RFA and SBRT: Regression
analysis
Regression analysis was conducted to adjust for the
different influence of clinical factors on effectiveness of
different treatment modalities. After adjusting for age and
percentage of stage IA, the corrected pooled 1-, 2-, 3-, and
5-year LCRs for SBRT were significantly higher than those012) included in the present meta-analysis
Median/mean age
(range) (y) IA/I (%) Path. (%)
Median (range)
F/U (mo)
66 (44-75) 39 100 12
78 (68-88) 58 100 28 (9-52)
69 (17-94) 75 NA 21 (3-74)
67 (29-82) 100 100 15 (1-30)
70 (31-94) NA NA 12 (3-60)
74 (62-83) NA 100 33
74 (40-88) 75 100 46 (12-82)
64 (42-82) 93 0 17.6 (2-31)
75 (52-88) 76 32 37 (2-88)
73  8 NA 100 56 (6-64)
65 (44-81) 75 100 23
72 (61-78) 25 100 9 y
70 (51-89) 82 100 32 (2-75)
stage IA disease; NAZ not reported or not specified; PZ prospective;
e.
Table 2 Characteristics of stereotactic body radiation therapy studies (2001-2012) included in the present meta-analysis
First author
(reference) Year
Study
design
Sample
size
Male
(%)
Median/
mean
age (range)
(y)
IA/I
(%) Path.(%) Dose range BED10 F/U (mo)
Nagata (37) 2005 P 45 74 77 (51-87) 71 100.0 12 Gy  4 105.6 30
Nyman (39) 2006 R 45 57 74 (58-84) 40 80.0 15 Gy  3 112.5 43 (24-74)
Timmerman (47) 2006 R 70 74 70 (51-86) 50 / 20 Gy  3 180 17.5 (0.6-44)
Zimmermann (51) 2006 R 68 71 76 100 100.0 12.5 Gy  3;
7 Gy  5 (at
60% isodose)
84.4; 59.5 17 (3-44)
Koto (33) 2007 P 31 81 77 (60-83) 61 100.0 15 Gy  3;
7.5 Gy  8
112.5; 105 32 (4-87)
Onishi (41) 2007 R 257 NA 74 (39-92) 64 NA 4.4w35/1-14 Fx 117 (100-180) 38 (2-128)
Fritz (30) 2008 R 40 80 74 (59-82) 55 100 30 Gy  1 120 Gy (isocenter) 20 (6-61.5)
Lagerwaard (34) 2008 R 206 57 73 59 31.0 20 Gy  3;
12 Gy  5;
7.5 Gy  8
132 12
Onimaru (40) 2008 P 41 69 76 (52-85) 61.0 NA 10 Gy  4;
12 Gy  4
80; 105.6 27
Salazar (43) 2008 R 60 NA NA 75 NA 13 Gy  4 119.6 NA
Baumann (6) 2009 P 57 44 75 (59-87) 70.2 NA 15 Gy  3 112.5 35 (4-47)
Fakiris (29) 2009 P 70 NA NA 48.6 NA 20 Gy  3 (IA);
22 Gy  3 (IB)
180; 211.2 50.2
Kopek (32) 2009 R 88 50 72 (47-88) 58.6 100.0 15/22.5 Gy  3 112.5; 219.5 44 (1.6-96.5)
Stephans (44) 2009 R 56 52 72 (49-89) 75.0 NA 10 Gy  5 100 19.8
Takeda (45) 2009 R 63 63 78 (56-91) 60.3 82.5 10 Gy  5 100 31 (10-72)
Baba (24) 2010 R 124 68 77 (29-89) 70.2 91.9 11 Gy  4 (1.6%);
12 Gy  4;
13 Gy  4
92.4; 105.6; 119.6 26 (7-66)
Bradley (25) 2010 P 91 47 71 (31-93) 72.5 86.3 18 Gy  3 151.2 18 (6-42)
Burdick (27) 2010 R 72 52 74 (44-89) 68.1 68.1 20 Gy  3;
10 Gy  5;
5 Gy  10
180; 100; 75 36
Dunlap (28) 2010 R 40 NA 73 (54-87) 67.5 100.0 42-60/3-5 Fx 150 12.5 (2-35)
Hamamoto (31) 2010 R 52 70 78 (58-90) 76.8 67.3 12 Gy  4 105.6 14 (3-34)
Ricardi (42) 2010 P 62 84 73 (53-83) 69.4 100.0 15 Gy  3 112.5 28 (9-60.7)
Timmerman (8) 2010 P 59 38 72 (48-89) 80.0 100.0 18 Gy  3 151.2 34.4 (4.8-49.9)
Van Der Voort
Van Zyp (49)
2010 P 39 NA 77 (55-87) 58.9 NA 20 Gy  3 180 17
Bral (26) 2011 P 40 83 73 (54-86) 65 100 20 Gy  3;
15 Gy  4
180; 150 16 (5-33)
Lanni (35) 2011 R 45 40 76 (63-90) 71 100 12 Gy  4;
12 Gy  5
105.6; 140 36
Matsuo (36) 2011 R 101 73 77 (62-87) 58.9 100.0 12 Gy  4 105.6 31.4 (4.2-118)
Nath (38) 2011 R 58 63 79 (60-88) 58.9 100.0 10 Gy  5;
12 Gy  4;
13 Gy  4
100; 105.6; 119.6 17 (4-42)
Turzer (48) 2011 R 36 28 74 (54-85) 53 73.7 15 Gy  3 112.5 13.8 (0-21)
Widder (50) 2011 P 202 73 76 (46-93) NA 29 20 Gy  3;
12 Gy  5;
7.5 Gy  8
180; 140; 105 13
Senthi (7) 2012 R 676 61 73 (47-92) 56 35 20 Gy  3 or
18 Gy  3;
12 Gy  5 or
11 Gy  5;
7.5 Gy  8
151$2; 115$5; 105 32.9 (14.9-50.9)
Taremi (46) 2012 P 108 49 73 (48-90) 79.6 69.4 20 Gy  3;
18 Gy  3;
12 Gy  4;
7.5 Gy  8;
5 Gy  10 (9.6%)
180; 151.2; 105.6;
105; 75
19.1 (1-55.7)
Abbreviations: BED10 Z biological equivalent dose with a/b Z 10; Fx Z fractions. Other abbreviations as in Table 1.
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Belfiore 2004 (n=66)
Simon# 2007 (n=69)
Simon* 2007 (n=69)
Okuma 2010 (n=70)
Hess 2011 (n=64)
Sofocleous 2011 (n=64)
Nagata# 2005 (n=73)
Nagata* 2005 (n=73)
Timmerman 2006 (n=70)
Zimmermann 2006 (n=76)
Koto# 2007 (n=77)
Koto* 2007 (n=77)
Onishi 2007 (n=74)
Fritz 2008 (n=74)
Onimaru 2008 (n=76)
Kopek 2009 (n=73)
Stephans# 2009 (n=74)
Stephans* 2009 (n=73)
Takeda# 2009 (n=31)
Takeda* 2009 (n=31)
Baba 2010 (n=77)
Bradley 2010 (n=71)
Burdick 2010 (n=74)
Hamamoto 2010 (n=68)
Ricardi 2010 (n=74)
Van Der Voort Van Zyp 2010 (n=77)
Bral 2011 (n=73)
Matsuo 2011 (n=77)
Senthi 2012 (n=73)
Taremi 2012 (n=73)
SBRT
0.0 0.2 0.4 0.6 0.8 1.0
0.0 0.2 0.4 0.6 0.8 1.0
RFA
Pennathur 2007 (n=78)
Simon# 2007 (n=69)
Simon* 2007 (n=69)
Okuma 2010 (n=70)
Sofocleous 2011 (n=64)
Nagata# 2005 (n=73)
Nagata* 2005 (n=73)
Timmerman 2006 (n=70)
Zimmermann 2006 (n=76)
Koto# 2007 (n=77)
Koto* 2007 (n=77)
Onishi 2007 (n=74)
Fritz 2008 (n=74)
Onimaru 2008 (n=76)
Kopek 2009 (n=73)
Stephans# 2009 (n=74)
Takeda# 2009 (n=31)
Takeda* 2009 (n=31)
Baba 2010 (n=77)
Bradley 2010 (n=71)
Burdick 2010 (n=74)
Hamamoto 2010 (n=68)
Dunlap 2010 (n=73)
Ricardi 2010 (n=74)
Van Der Voort Van Zyp 2010 (n=77)
Bral 2011 (n=73)
Matsuo 2011 (n=77)
Senthi 2012 (n=73)
Nath 2011 (n=79)
Taremi 2012 (n=73)
SBRT
RFA
1–year local control rate
2–year local control rate
A
B
Fig. 2. Overview of local control rate and 95% confidence intervals for all studies and pooled estimates. Local control
rates at 1 year (A) 2 years (B), 3 years (C), and 5 years (D) are shown. Abbreviations: RFA Z radiofrequency ablation;
SBRT Z stereotactic body radiation therapy.
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Simon# 2007 (n=69)
Simon* 2007 (n=69)
Okuma 2010 (n=70)
Ambrogi 2011 (n=74)
Hiraki 2011 (n=75)
Sofocleous 2011 (n=64)
Lanuti 2012 (n=70)
Simon# 2007 (n=69)
Simon* 2007 (n=69)
Okuma 2010 (n=70)
Kim 2011 (n=72)
Lee 2011 (n=72)
RFA
RFA
Nagata# 2005 (n=73)
Nagata* 2005 (n=73)
Nagata# 2005 (n=73)
Nagata* 2005 (n=73)
Timmerman 2006 (n=70)
Timmerman 2010 (n=72)
Zimmermann 2006 (n=76)
Koto# 2007 (n=77)
Koto* 2007 (n=77)
Koto# 2007 (n=77)
Koto* 2007 (n=77)
Onishi 2007 (n=74)
Onishi 2007 (n=74)
Fritz 2008 (n=74)
Onimaru 2008 (n=76)
Baumann 2009 (n=75)
Fakiris 2009 (n=N/A)
Stephans# 2009 (n=74)
Kopek 2009 (n=73)
Takeda# 2009 (n=31)
Takeda* 2009 (n=31)
Baba 2010 (n=77)
Baba 2010 (n=77)
Bradley 2010 (n=71)
Burdick 2010 (n=74)
Ricardi 2010 (n=74)
Lanni 2011 (n=76)
Matsuo 2011 (n=77)
Senthi 2012 (n=73)
Taremi 2012 (n=73)
SBRT
Matsuo 2011 (n=77)
Senthi 2012 (n=73)
SBRT
3–year local control rate
5–year local control rate
0.0 0.2 0.4 0.6 0.8 1.0
0.0 0.2 0.4 0.6 0.8 1.0
C
D
Fig. 2. (continued).
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ablation and SBRT did not have statistically significantly
different 1-, 2-, 3-, and 5-year OS (Table E1; available
online at www.redjournal.org).
Occurrence of adverse events
The total occurrence of each adverse event per treatment
modality, as well as the number of patients at risk, is listedin Table E2 (available online at www.redjournal.org).
Overall, both RFA and SBRT studies reported limited se-
vere adverse events. The most frequent complication of
RFA was pneumothorax (grade 1), which was reported in
31% (95% CI 19%-43%) of patients. Severe pneumothorax
that required intervention (grade 3) occurred in 13%
(95% CI 0%-27%) of patients. The most frequent grade 3
or greater toxicity for SBRT was radiation pneumonitis,
occurring in 2% of patients (95% CI 1%-4%). The second
Table 3 Results of meta-analysis for local control rate (LCR)
Time
SBRT RFA
P P*Number of study LCR 95% CI Number of study LCR 95% CI
1 year 20 0.97 0.96-0.98 5 0.77 0.70-0.85 <.001 <.001
2 year 22 0.92 0.91-0.94 4 0.48 0.37-0.58 <.001 <.001
3 year 21 0.88 0.86-0.90 6 0.55 0.47-0.62 <.001 <.001
5 year 6 0.86 0.85-0.88 4 0.42 0.30-0.54 <.001 .04
Abbreviations: CI Z confidence interval; RFA Z radiofrequency ablation; SBRT Z stereotactic body radiation therapy.
* Corrected by age and percentage of stage IA.
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patients (95% CI 1%-3%). The incidence of severe (grade
3) acute esophageal toxicity, however, was uncommon.
Several studies also reported cases of grade 3/4 adverse
events, but because they did not specify the types of
adverse events, these were not incorporated into the count.Discussion
To our knowledge, this is the first systemic review and
pooled analysis to compare the efficacy and morbidity of
RFA and SBRT for medically inoperable early-stage
NSCLC. A total of 44 studies, 13 for RFA and 31 for SBRT,
were used in the comparison. The 1-, 2-, 3-, and 5-year
LCRs, corrected for differences in each study’s proportions
of stage IA and age, were significantly higher after SBRT
than those after RFA treatment. The OS rates for RFA and
SBRT were comparable. Both SBRT and RFA reported
limited risk of severe toxicity.
A number of literature reviews that separately addressed
the effectiveness of SBRT and RFA were published
recently (52, 53, 54, 55, 56). However no actual pooled
analysis has been published to date. Recently Bial et al (57)
performed an English literature review to compare RFA
with SBRT in patients with early-stage medically
inoperable NSCLC. A total of 16 studies (9 studies for RFA
and 7 studies for SBRT) were used to answer this question.
They found that the OS at 1 year (68.2%-95% vs
81%-85.7%) and 3 years (36%-87.5% vs 42.7%-56%) was
similar between patients treated with RFA and stereotactic
ablative radiation therapy, whereas 5-year OS was higher
for SBRT (47%) than for RFA (20.1%-27%). Local
progression rates were lower in patients treated with
SBRT (3.5%-14.5% vs 23.7%-43%). These results were
different from the pooled estimates presented in the current
study, showing better local control without significant
difference in 5-year survival. The difference might be
explained by 2 main factors. First, Bial et al (57) did not
use a statistical approach to analyze all the data. Second,
our analysis included more studies, and especially recently
published studies. We used 8 studies for RFA and 10
studies for SBRT that reported 5-year OS results, whereas
only 2 RFA studies and 1 SBRT study were included in
Bial’s review.A cost-effectiveness analysis published by Sher et al (58)
compared conventional RT, SBRT, and RFA for medically
inoperable stage I NSCLC. They developed aMarkovmodel
to describe health states of 65-year-old men with medically
inoperable NSCLC after treatment with 3-dimensional
conformal radiation therapy (3D-CRT), SBRT, and RFA.
They found that SBRTis themost cost-effective treatment for
medically inoperable stage I NSCLC. The incremental cost-
effectiveness ratio for SBRT over 3D-CRT was $6000 per
quality-adjusted life-year, and the incremental cost-
effectiveness ratio for SBRT over RFA was $14,100 per
quality-adjusted life-year. However, these results were based
on a wide range of assumptions, including the efficacy of
each treatment modality. For example, the local recurrence
rates they used for RFA treatment was only derived from 1
retrospective study, published by Simon et al (21). The 3-year
LCR for RFA in that study was only 43%, which was
significantly lower than pooled result (55%, 95% CI 47%-
62%) from this study. The possible explanation of this dif-
ference is that the study by Simon et al included not only
primary early-stage NSCLC but also metastatic lung cancer
(more than 40%). Because the local recurrence risk of RFA is
one key variable that could change the outcome of cost-
effectiveness analysis, our pooled estimate results on SBRT
and RFAmight be helpful to improve the predictive accuracy
of their model.
A strong correlation between the size of the targeted
tumors and the RFA treatment results has been reported.
Higher rates of relapse were noted in tumors larger than 2
to 4 cm. Simon et al (21) reported on 75 patients with stage
I NSCLC who were treated with RFA and followed
for 5 years; the 5-year progression-free survival was
significantly higher in tumors <3 cm (47%) compared with
larger tumors (25%). Okuma et al (13) identified that the
significant risk factor for local progression after RFA was
tumor size 2 cm (hazard ratio 1.5, 95% CI 1.2-2.0),
whereas Huang et al (59) indicated that significant
difference in the risk of local progression was found in
tumors >4 cm. A recent study including 55 ablations in 45
patients with stage I NSCLC reported more local failures in
tumors >3 cm (80%), compared with lesions <3 cm (29%)
(19). All this evidence suggested that the difference in the
percentage of small tumors (<3 cm, stage IA patients)
between the study populations might significantly influence
the outcome. Therefore, in the present study we performed
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Volume 95  Number 5  2016 SBRT v RFA in inoperable stage I NSCLC 1387a regression analysis and found that after correcting
for differences in tumor size (the percentage of stage
IA patients), the local tumor control rates at 1, 2, 3, and
5 years were still significantly better for SBRT compared
with RFA (P<.001 at 1 year, 2 years, and 3 years; PZ.04 at
5 years).
Although the LCR was significantly higher in patients
treated with SBRT, the pooled estimates of OS between
SBRT and RFA were similar. These results were consistent
with those of a recent prospective study (60) that included
116 patients treated with sublobar resection (nZ42), RFA
(nZ25), or radiation therapy (nZ49). After adjusting forage and tumor size, a significant difference in the partial
response (PR) PR rate was observed, but no significant
differences in OS. The comparison of long-term survival
outcomes assessing alternate therapies for high-risk pa-
tients is challenging because the comorbidity and mortality
rates are high. Evidence showed that even without any
cancer, the median 5-year OS for patients with severe
chronic obstructive pulmonary disease was only approxi-
mately 40% (61). As many as one-third of medically
inoperable patients with NSCLC would die from comorbid
conditions rather than cancer (55). It has been suggested
that for medically inoperable patients with NSCLC, local
Bi et al. International Journal of Radiation Oncology  Biology  Physics1388tumor control and relapse-free survival might be more valid
endpoints than OS (54).
Although our study demonstrated that the local tumor
control was significantly better for SBRT than for RFA
treatment, there are certainly a number of limitations. First,
this is a systemic review and pooled analysis based on
observational studies. When combining observational
studies, heterogeneity of populations, design, and outcome
are expected, and these differences may influence the
pooled estimates. However, despite these challenges, when
no randomized, controlled trials or retrospective studies
directly comparing RFA and SBRT are available, a sys-
temic review and pooled analysis of observational studies
might be a valid method for assessing efficacy and effec-
tiveness, and could provide useful evidence to inform the
decision whether more evidence is needed. Moreover, a
regression analysis could correct for some potential dif-
ferences between study populations or designs. Second,
most RFA studies were small case series with relatively
short follow-up, which led to wide variance of LCRs and
OS estimated by formula. Four RFA studies were newly
published (60, 62-64) while we were preparing this article.
A local progression rate of more than 20%, 1-year LCR of
68.9%, and 2-year LCR of 59.8% were reported, which
were similar to our pooled results. Third, definitions of
local progression are not always consistent across the
published reports. The wide range (3-50%) of local tumor
progression after earlier RFA studies may be partially
explained by these variations. Last, we did not look at trials
presented only in their abstract form or at unpublished
studies, nor at studies without separate data for early-stage
NSCLC patients. This emphasizes the importance that au-
thors should fully document the characteristics of the study
populations in their articles.
In conclusion, this systemic review and pooled analysis
demonstrated that SBRT provided superior 1-, 2-, 3-, and 5-
year local tumor control over RFA, even when corrected for
patients’ age and tumor size 3 cm. Therefore, at present,
SBRT is still the most effective local treatment for inop-
erable stage I NSCLC patients, and RFA should be offered
only if patients are not candidates for SBRT. However,
caution should be taken owing to the relatively limited
number of RFA trials and short follow-up time. More
studies with larger sample sizes for RFA treatment are
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